ImmunityBiovsJohnson & Johnson

IBRX and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

IBRX

ImmunityBio, Inc.

$6.26

Value $6.4B

+4.68%
IBRX's page

ImmunityBio (IBRX) has a market value of $6.4B and Johnson & Johnson (JNJ) $672B. Over the last year, with dividends, IBRX moved +201.0% and JNJ +45.4%. Dividend yield: IBRX none, JNJ 1.89%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    IBRX$6.4B

    JNJ$672B

    JNJ is 104 times IBRX

  • Revenue, 12 months

    IBRX$183M

    JNJ$99.3B

    JNJ is 544 times IBRX

  • Net income, 12 months

    IBRX-$1.1B

    JNJ$16.1B

  • Operating margin

    IBRX-150.2%

    JNJ–

  • ROIC

    IBRX–

    JNJ12.4%

  • P/E

    IBRX–

    JNJ41.7

  • Dividend yield

    IBRX0.0%

    JNJ1.9%

    1.9 points apart

  • 5-year return

    IBRX-11.5%

    JNJ+97.0%

    108.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

IBRX-11.5%

JNJ+97.0%

10020020222023202420252026
Returns by period
PeriodIBRXWith dividendsJNJWith dividends
1 year since November 14, 2025+201.0%Price +201.0%+45.4%Price +42.2%
3 years since November 17, 2023+51.2%+14.8% a yearPrice +51.2%+102.6%+26.5% a yearPrice +86.1%
5 years since November 16, 2021-11.5%-2.4% a yearPrice -11.5%+97.0%+14.5% a yearPrice +71.3%
10 years since November 17, 2016-16.5%-1.8% a yearPrice -16.5%+213.7%+12.1% a yearPrice +139.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

IBRXImmunityBioJNJJohnson & Johnson

Valuation

IBRXJNJ
Valuation
Price$6.26$278.70
Market value$6.4B$672B
Enterprise value (EV)–$699B
P/E–41.7
P/E, 5-year median–21.9
P/B–8.2
EV/EBIT–39.4
Free cash flow yield–3.1%

Results and growth

IBRXJNJ
Results and growth
Revenue, 12 months$183M$99.3B
Net income, 12 months-$1.1B$16.1B
Free cash flow, 12 months-$297M$20.6B
Earnings per share, 12 months-$1.08$6.59
Revenue growth, year on year668.3%6.1%
Revenue growth a year, past+184.8%over 5 years+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

IBRXJNJ
Margins and returns on capital
Gross margin98.8%67.6%
Operating margin-150.2%–
Net margin-607.8%16.2%
ROIC–12.4%
ROE–19.7%

Balance sheet

IBRXJNJ
Balance sheet
Cash$334M$17.2B
Total debt–$44.7B
Net debt / EBITDA–1.1
Interest cover-4.5×18.0×

Dividends and buybacks

IBRXJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: IBRX or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, ImmunityBio or Johnson & Johnson?

By market value, Johnson & Johnson ($672B) is about 104.4 times ImmunityBio ($6.4B), at today's prices.

How did IBRX and JNJ stock do over the last 10 years?

Since November 17, 2016, IBRX's price moved -16.5% and JNJ's +139.1%. With dividends: IBRX -16.5% (-1.8% a year), JNJ +213.7% (+12.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, IBRX or JNJ?

The dividend yield at today's price is none for ImmunityBio and 1.89% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which has the higher profit margins, ImmunityBio or Johnson & Johnson?

Over the last twelve months, the net margin was -607.8% for ImmunityBio and 16.2% for Johnson & Johnson, and the operating margin -150.2% and –. Revenue was $183M and $99.3B.

Which is the better investment, ImmunityBio or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.